PMID- 18476983
OWN - NLM
STAT- MEDLINE
DCOM- 20090727
LR  - 20181201
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 10
IP  - 12
DP  - 2008 Dec
TI  - Rosiglitazone and pioglitazone similarly improve insulin sensitivity and 
      secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
PG  - 1204-11
LID - 10.1111/j.1463-1326.2008.00880.x [doi]
AB  - OBJECTIVE: We examined the effects of rosiglitazone treatment on profiles of 
      adipocytokines levels, postprandial insulin and glucose excursion, lipids levels, 
      comparing with those of pioglitazone treatment in patients with type 2 diabetes 
      mellitus (T2DM). METHODS: Changes in body weight, haemoglobin A(1c )(HbA(1c)), 
      glucose/insulin/C-peptide/free fatty acid (FFA) during 75 g oral glucose 
      tolerance test (OGTT), HDL-/LDL-cholesterol, triglyceride (TG) and adipocytokines 
      [tumour necrosis factor (TNF)-alpha, leptin and adiponectin] were measured in 
      T2DM patients treated with rosiglitazone, 8 mg/day (n = 35), or pioglitazone, 45 
      mg/day (n = 21), for 3 months. RESULTS: After rosiglitazone or pioglitazone 
      treatment, HbA(1c )(8.6-7.2 vs. 8.3-6.9%, rosiglitazone vs. pioglitazone), 
      fasting plasma glucose (190-144 vs. 178-140 mg/dl), fasting FFA (729-595 vs. 
      641-526 microEq/l), mean plasma glucose-OGTT (292-229 vs. 285-233 mg/dl) and mean 
      FFA-OGTT (580-430 vs. 488-377 microEq/l) decreased similarly and all were 
      statistically significant (p < 0.01). The insulinogenic index 
      (DeltaI(0-120)/DeltaG(0-120)) (0.19-0.30 vs. 0.17-0.26) and Matsuda index of 
      insulin sensitivity (2.0-3.1 and 2.7-4.3) increased (p < 0.01) similarly, despite 
      increase in body weight (85-88 vs. 81-84 kg). TNF-alpha (3.8-3.4 vs. 5.2-4.5 
      pg/ml) decreased (p < 0.05) and adiponectin (6.3-17.8 vs. 7.1-16.4 microg/ml) 
      increased (p < 0.01), while leptin did not change following either treatment. 
      After rosiglitazone treatment, plasma HDL-cholesterol (34-38 mg/dl) and 
      LDL-cholesterol (103-120 mg/dl) increased (p < 0.01), while TGs (177-167 mg/dl) 
      did not change significantly. After pioglitazone treatment, plasma 
      HDL-cholesterol (34-37 mg/dl) increased (p < 0.05), while LDL-cholesterol 
      (104-105 mg/dl) did not change and TGs (153-106 mg/dl) decreased (p < 0.01). 
      CONCLUSIONS: Rosiglitazone and pioglitazone have similar beneficial effects on 
      glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine 
      levels. However, pioglitazone has a more beneficial effect on the plasma lipid 
      profile than rosiglitazone.
FAU - Miyazaki, Y
AU  - Miyazaki Y
AD  - Department of Medicine, Diabetes Division, University of Texas Health Science 
      Center, San Antonio, TX 78229-3900, USA.
FAU - DeFronzo, R A
AU  - DeFronzo RA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20080512
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Adipokines)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adipokines/blood
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*blood
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Postprandial Period/drug effects
MH  - Rosiglitazone
MH  - Thiazolidinediones/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2008/05/15 09:00
MHDA- 2009/07/28 09:00
CRDT- 2008/05/15 09:00
PHST- 2008/05/15 09:00 [pubmed]
PHST- 2009/07/28 09:00 [medline]
PHST- 2008/05/15 09:00 [entrez]
AID - DOM880 [pii]
AID - 10.1111/j.1463-1326.2008.00880.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2008 Dec;10(12):1204-11. doi: 
      10.1111/j.1463-1326.2008.00880.x. Epub 2008 May 12.